Investing
Skyharbour Announces Closing of Private Placement for Gross Proceeds of C$10 Million
Not For Distribution to U.S. News Wire Services or Dissemination in The United States Vancouver, BC, Dec. 20, 2024 (GLOBE...
Read more
Silver Price Forecast: Top Trends That Will Affect Silver in 2025
The silver price reached highs not seen since 2012 this past year, supported by an ongoing deficit and increasing interest...
Read more
Top 5 Canadian Mining Stocks This Week: Omineca Jumps 67 Percent
The S&P/TSX Venture Composite Index (INDEXTSI:JX) fell 2.87 percent on the week to close at 586.88 on Friday (December 20)....
Read more
Opawica Announces the Closing of Non-Brokered Private Placement
(TheNewswire) December 20th, 2024 Vancouver, B.C. TheNewswire – Opawica Explorations Inc. (TSXV: OPW) (FSE: A2PEAD) (OTCQB: OPWEF) (the ‘Company’ or...
Read more
Awalé Expands BBM Trend to Over 15km with Additional Newly Defined Targets Boba and Fett
HIGHLIGHTS BBM trend now extends over 15km, from Awalé’s 100%-owned Fremen target in the south to the Boba and Fett...
Read more
Hempalta Corp. Announces Financial Results for Year Ended September 30, 2024
AgTech Company highlights recent 100% purchase of Hemp Carbon Standard platform to advance industrial hemp carbon credits global market opportunity...
Read more
Forum Comments on Share Price
Forum Energy Metals Corp. (TSXV: FMC) (OTCQB: FDCFF) (‘Forum’ or the ‘Company’) announced today that the Company is not aware...
Read more
Opawica Explorations Inc Begins Field Work in Preparation of Upcoming Drill Campaign at Its Bazooka Property in the Abitibi Gold Belt
(TheNewswire) December 19th, 2024 TheNewswire – Vancouver, B.C. Opawica Explorations Inc. (TSXV: OPW) (FSE: A2PEAD) (OTCQB: OPWEF) (the ‘Company’ or...
Read more
RAD 202 receives approval to start Phase 1 therapeutic trial
Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial Download the PDF here. This...
Read more
PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx Addressing Patients with Recurrent Pericarditis
Cardiol Therapeutics President and CEO, David Elsley PRISM MarketView announces the release of an informative interview with Cardiol Therapeutics President...
Read more
